Introduction
Photodynamic therapy of cancer involves the activation of a photosensitizer by light to induce localised cell death. The naturally-occurring heme precursor 5-aminolevulinic acid (ALA) is used as a pro-drug in photodynamic therapy of a wide variety of different solid tumors (Peng et al., 1997; Krammer and Plaetzer, 2008) . ALA is converted by the heme biosynthesis pathway into the photosensitizer protoporphyrin IX (PpIX), which, when exposed to long wavelength light, releases highly reactive singlet oxygen (Kennedy and Pottier, 1992) . Topical or systemic application of ALA leads to selective accumulation of PpIX within tumor cells which reduces non-specific tissue damage during photodynamic therapy (Kennedy and Pottier, 1992) . This selectivity has also been exploited in diagnosis and fluorescent-guided resection of tumors (e.g. malignant glioma) where accumulated PpIX makes tumors fluoresce under illumination (Stummer et al., 2006) . The molecular basis of the tumor-selective PpIX accumulation is not clear, although altered activity of enzymes in the heme biosynthesis pathway, which convert ALA to PpIX and PpIX to heme, has been suggested (Kennedy and Pottier, 1992; van Hillegersberg et al., 1992) .
ALA is rapidly cleared from the body which reduces potential side-effects such as enduring cutaneous photosensitivity following treatment (Loh et al., 1993; van den Boogert et al., 1998) . One of the key advantages of ALA-based therapy is its good oral bioavailability. In rats, oral ALA produces a plasma ALA level within one hour similar to that achieved by i.v. delivery of an equivalent dose (van den Boogert et al., 1998) . Oral dosage with ALA is also used in photodynamic therapy of gastrointestinal tumors. However, relatively high doses of ALA are required to produce adequate PpIX tumor/normal mucosa ratios, due to the high background accumulation in normal epithelial cells (Loh et al., 1993; Regula et al., 1995; Peng et al., 1997) . 
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One of the unanswered questions of ALA-based therapy is how the hydrophilic ALA is absorbed from the lumen of the gastrointestinal tract. There is convincing evidence that the intestinal H + -coupled di/tripeptide transporter PepT1 (SLC15A1) can transport ALA (Döring et al., 1998) and so may be involved in ALA transport across the intestinal epithelial brushborder membrane. However, the structure of ALA is also analogous to that of the neuroactive amino acid GABA suggesting that ALA may also interact with a GABA uptake system. To test this hypothesis, ALA transport by the H + -coupled amino acid transporter PAT1 (SLC36A1; Boll et al., 2002; Chen et al., 2003) was measured. PAT1 mediates uptake of GABA, other small neutral amino acids (e.g. proline, glycine, taurine) and a large number of related amino acid analogues across the apical membrane of intestinal epithelial cells (Thwaites et al., 1995; Anderson et al., 2004; Metzner et al., 2006; Thwaites and Anderson, 2007a) . PAT1 can also transport therapeutic GABA analogues such as vigabatrin and gaboxadol (Abbot et al., 2006; Larsen et al., 2009 ) which may account for the excellent bioavailability of these drugs when given orally. PAT1 transport, like that of PepT1, is driven by the H + -electrochemical gradient that exists due to an area of low pH adjacent to the intestinal luminal surface called the acid microclimate (McEwan et al., 1988; Thwaites and Anderson, 2007b) . Using a combination of heterologous expression in Xenopus laevis oocytes and endogenous expression in Caco-2 cell monolayers, we show that PAT1 is a novel pH-dependent, rheogenic H + /ALA transporter and that both PAT1 and PepT1 contribute to ALA uptake across the brush-border membrane of intestinal epithelial cells. We also consider the possibility that ALA transport may contribute to selective PpIX accumulation within tumor cells after observing increased expression of PepT1, but not PAT1, mRNA in colon cancer.
This article has not been copyedited and formatted. The final version may differ from this version. Expression in Xenopus laevis oocytes. Oocytes were isolated as described previously (Anderson et al., 2004) . cRNA was synthesised by in vitro transcription either using the mMessage mMachine T7 kit (Ambion, Warrington, UK) (PAT1) or as described previously (Kennedy et al., 2002) (PepT1) . Oocytes were injected with 50nl cRNA (1 mg/ml) or water (as a control) and maintained for at least 2 days before use, as described previously (Anderson et al. 2004 ). (You et al., 1993) this would equate to an intracellular β-alanine concentration of approximately 8mM. After injection, oocytes were allowed to recover for 15min before washing and measurement of efflux in uptake solution (as above, pH 5.5) for 10min at 22°C. Efflux was measured in the presence and absence of potential transstimulating compounds (20mM). The amount of radioactivity effluxed into the uptake solution was then measured by scintillation counting.
Two-electrode voltage-clamp.
Oocytes were clamped at -60mV whilst being superfused with Na + -free pH 5.5 buffer in the presence or absence of various compounds (see figure legends for details). Current changes associated with H + -coupled transport were measured using a Geneclamp 500 amplifier, Digidata 1200 (Axon Instruments) and pClamp software. To determine the current evoked by a substrate, the current measured over the last 15s of the exposure time was averaged. The baseline current (taken as the average current over the 15s before exposure to the substrate) was then subtracted. Current-voltage (I-V) relationships were determined by clamping membrane potential at -60mV then stepping sequentially between -100 and +80mV in 20mV steps (each for 200ms). I-V measurements made in the absence of a substrate were subtracted from those made when substrate-induced current flow reached steady-state.
Uptake measurements in Caco-2 cell monolayers. Caco-2 cells were grown as confluent monolayers of polarised cells on Transwell polycarbonate filters (Corning, Schiphol-Rijk, The Netherlands), as described previously (Thwaites et al., 1995) . Prior to uptake, Caco-2 cell monolayers were washed (4 x 500ml) and bathed in Na H]D-Phe-Gln (all 0.5μCi/ml, 100μM) was measured over 5-15min at 37°C, apical pH 7.4 or pH 5.5 (HEPES substituted with MES) and basolateral pH 7.4. Monolayers were washed immediately in ice-cold solution (3 x 500ml) and removed from the plastic inserts to allow radioactivity to be measured by scintillation counting.
Tissue collection. Eighteen adult patients with colorectal cancer were included after obtaining their informed consent and Medical College of Georgia institutional review board's approval (Gupta et al., 2006) . Samples 1-6 were from patients GM1-GM6, sample 7 from GM18, samples 8-16 from GM 24-32, sample 17 from GM34, and sample 18 from GM36 (see Gupta et al., 2006 , for patient details). Total RNA from mucosal samples (paired normal and cancer samples) was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer's instructions.
Reverse transcriptase-polymerase chain reaction (RT-PCR).
RNA was reversed transcribed using the GeneAmp PCR system (Applied Biosystems, Branchburg, NJ). PCR was carried out using the following primers: PepT1, forward GGCTGGACTGGGCTAAAGAGAAATACGATG, reverse GTTGGCCCTGCTTGAAGTCGTCAGTTAC; PAT1, forward CCACCAATAACTGCCACAACAATGAGACGG, reverse TGCGCACAAACAGGTCCACCACTAACTCAC. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a universal control. The levels of PAT1 and PepT1
were quantified by densitometry scanning and normalized to the intensities of the corresponding GAPDH bands.
Data Analyses. Data are expressed as mean ± SEM. For all radiolabel transport measurements, experiments were repeated two to three times using at least 9-10 oocytes per condition within each replicate, or 5-6 Caco-2 cell monolayers per condition within each This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1A) . ALA uptake at pH 5.5 was inhibited by the PAT1 substrates β -alanine and GABA (both 20mM, Fig. 1B ). To characterize PAT1-mediated ALA uptake, rheogenic transport (consistent with H + /zwitterion symport) was measured as inward positive charge movement by the two-electrode voltage-clamp technique ( Fig. 1 C, D) . ALA caused inward current in oocytes heterologously expressing PAT1 but not in control oocytes (Fig. 1D ). The current induced by ALA was consistently smaller than for GABA and β -alanine (Fig. 1C, D) . The affinity of PAT1 for ALA (K m = 10.4 ± 5.6mM; shown in Fig. 1F) was also lower than for GABA (K m = 1.1 ± 0.5mM, data not shown).
Transport of ALA via PepT1. A previous study by Daniel and colleagues identified that the intestinal di/tripeptide transporter PepT1 could transport ALA (Döring et al., 1998 (Fig. 1E ) and the affinity of PepT1
for ALA (K m = 1.6 ± 0.9mM, Fig. 1F ) was comparable to that reported previously for Gly-Sar Fei et al., 1994) .
This article has not been copyedited and formatted. The final version may differ from this version. 
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Characterisation of non-transported inhibitors of PAT1 and PepT1. Figure 1 shows clearly that, despite their distinct substrate specificities, both the amino acid transporter PAT1 and the di/tripeptide PepT1 can transport ALA in a pH-dependent, H + -coupled manner.
Previous studies have identified both PAT1 and PepT1 at the apical membrane of the small intestinal epithelium (and the model cell line Caco-2) (Walker et al., 1998; Chen et al., 2003) where they may both play important roles in nutrient and drug absorption (Rubio-Aliaga and Thwaites and Anderson, 2007a) . To identify whether both PAT1 and PepT1 play roles in ALA uptake across the brush-border membrane of the small intestinal epithelium it was necessary to use non-transported inhibitors of each transporter. Such inhibitors will mitigate any potential interaction caused by changes in pH i associated with the saturating concentrations of transported substrates normally used in competition experiments.
5-Hydroxy-L-tryptophan (OH-Trp) has been proposed as a non-transported inhibitor of PAT1 (Metzner et al., 2005 ). Uptake of [ 3 H]β-alanine by PAT1 expressed in oocytes was inhibited in a concentration-dependent manner by OH-Trp (IC 50 = 1.2 ± 0.3mM; Fig. 2A ).
OH-Trp (20mM) caused no current change in PAT1 oocytes but could inhibit current induced by β -alanine (2mM) by 89% (p<0.001; Fig. 2B ). This observation suggests that OH-Trp is either a non-transported inhibitor or possibly a substrate transported in a non-rheogenic manner. Consistent with being a non-transported inhibitor, extracellular OH-Trp (20mM) was unable to trans-stimulate PAT1-specific efflux of β-alanine from oocytes (p>0.05) whereas the PAT1 substrates GABA and proline (20mM) caused significant trans-stimulation (p<0.001, Fig. 2C ). As a control, the amino acid glutamate (20mM), which is not a substrate for PAT1 (Thwaites et al., 1995) , was included and did not cause trans-stimulation. PAT1- 
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A non-transported inhibitor of PepT1 was discovered due to its ability to inhibit dipeptide uptake but inability to cause trans-stimulation (Meredith et al., 1998) . 4-aminomethylbenzoic acid (AMBA) inhibited [ 14 C]Gly-Sar uptake into PepT1-expressing oocytes (IC 50 = 4.4 ± 1.5mM; Fig. 3A) . AMBA (30mM) induced no current in PepT1-expressing oocytes suggesting that PepT1 does not transport AMBA (Fig. 3B) . At 30mM, AMBA significantly inhibited (p<0.001) current caused by 1mM Gly-Sar (Fig. 3B, C) .
Similarly, 30mM AMBA inhibited PepT1-mediated [ 3 H]ALA uptake by 82% (Fig. 3D) . The dipeptide Val-Val (20mM) completely inhibited PepT1-mediated [ 3 H]ALA uptake (Fig. 3D) .
Importantly, the PAT1 inhibitor OH-Trp had no effect (p>0.05) on PepT1-mediated [ 3 H]ALA uptake ( Fig. 3D ) and the PepT1 inhibitor AMBA had no effect (p>0.05) on PAT1-mediated Both PAT1 and PepT1 mediate ALA uptake at the intestinal brush-border membrane. Caco-2 cell monolayers grown on permeable supports are frequently used as a model of the small intestinal epithelium. The interaction of ALA with amino acid transport at the intestinal brush-border membrane was assessed (Fig. 4A) . Uptake of the PAT1 substrates β -alanine, GABA, glycine, L-proline and MeAIB were all significantly reduced by ALA (10mM; p<0.01; Fig. 4A ). In contrast, the uptake of amino acids not transported by PAT1, such as lysine and methionine (Thwaites et al., 1995) , were unchanged in the presence of ALA (p>0.05). The inhibition of [ 3 H]β-alanine uptake by ALA was concentration-dependent (Fig. 4B) . The IC 50 for ALA inhibition of apical amino acid uptake in Caco-2 cells (7.1 ± 0.9mM) was close to the affinity constant estimated by electrophysiology in PAT1-expressing oocytes (Fig. 1 5C ) and had no effect on uptake of [ 3 H]β-alanine (Fig. 5B ). These data confirm that the two inhibitors, OH-Trp and AMBA, are selective for PAT1 and PepT1, respectively, in a cell system where both transporters are coexpressed in the same cell membrane. Therefore, these data demonstrate that both PAT1 and PepT1 contribute to ALA transport across the brush-border membrane of intestinal epithelial cells (Fig. 5A ). It should be noted that AMBA (30mM) does not completely inhibit dipeptide uptake (Fig. 5C) . Therefore, the degree of inhibition by AMBA observed in Fig. 5A 14 has been a useful experimental tool in this investigation, as it negates potential non-specific effects on driving force.
Expression of PAT1 and PepT1 in colon cancer. For increased conversion of oral
ALA to PpIX to occur in tumors, accumulation of ALA within tumor cells is firstly required.
Therefore, expression of PAT1 and PepT1 in colon cancer and normal tissue was investigated (Fig. 6 ). Eighteen paired biopsy samples from patients with colorectal cancer were screened for PAT1 and PepT1 expression at the mRNA level (Fig. 6A) . The relative expression of PAT1 was not significantly different between normal and tumor tissue (Fig. 6B) which may indicate that PAT1 contributes to ALA accumulation in both normal and tumor intestinal mucosa. However, PepT1 expression was increased in all eighteen tumor samples, with an average increase of 2.3 ± 0.1 fold (Fig. 6B) . Therefore, it is conceivable that increased 
Discussion
The H + -coupled amino acid transporter PAT1 acts as a high capacity, absorptive route for small neutral amino acids, such as GABA, and many orally-active analogues across the brush-border membrane of the small intestine (Thwaites et al., 2000; Chen et al., 2003; Anderson et al., 2004; Abbot et al., 2006; Metzner et al., 2006; Thwaites and Anderson, 2007a; Larsen et al., 2009 ). PAT1 can also be considered a novel intestinal transporter of the heme precursor ALA which is used extensively in photodynamic therapy. PAT1 has a relatively low affinity for ALA (K m 10.4mM; Fig. 1A ) compared with GABA (K m 1.1mM), but the affinity is within the range of that for other naturally-occurring PAT1 substrates such as glycine, L-proline, L-alanine and taurine (K m ~2-10mM; Thwaites et al., 1995; Boll et al., 2002; Metzner et al., 2006; Anderson et al., 2009 ).
During photodynamic therapy, ALA is typically given orally in the range 10-60mg/kg body weight, in small amounts of fluid, either as a bolus or in fractionated doses. The low molecular weight of ALA (mol. wt. 167) makes it conceivable that concentrations around the K m of PAT1 are achieved in the intestinal lumen.
The data presented here show that ALA transport across the brush-border membrane of the human small intestinal epithelium is via both PAT1 and the H + -coupled di/tripeptide transporter PepT1 (Fig. 5 ). Understanding the mechanisms by which ALA is transported across the brush-border membrane is essential when considering the potential for patient variability either through polymorphisms, drug-drug interactions or pathophysiological regulation of intestinal function. Both PAT1 and PepT1 are regulated by a range of dietary, (patho)physiological and neurohormonal pathways Daniel, 2004; Thwaites and Anderson, 2007a) 
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As ALA readily appears in the plasma after oral dosage (van den Boogert et al., 1998) , it must also be transported, intact, across the basolateral membrane of the small intestinal epithelium. There is some evidence that this may be via the, as yet unidentified, basolateral di/tripeptide transporter described in cell cultures (Irie et al., 2001) . In other cells, ALA transport may be via either amino acid or peptide transporters. A common transport system for ALA, and the structurally analogous GABA, was first shown in Saccharomyces cerevisiae (Bermúdez Moretti et al., 1995) . Around the same time, studies in bacteria identified ALA transport via a dipeptide permease (Elliott, 1993) . Daniel and colleagues (Döring et al., 1998) were first to show that ALA is an excellent substrate not only for PepT1 but also for nonintestinal PepT2 (SLC15A2). Subsequently, PepT1 was shown to mediate ALA transport in cholangiocytes where its affinity for the transporter (K m 2.1mM) is similar to that for PepT1 in this study (Fig. 2; Neumann and Brandsch, 2003) . Studies using knockout mice demonstrate that PepT2 plays a key role not only in ALA reabsorption in the kidney but also in limiting ALA neurotoxicity by removal of ALA from the cerebrospinal fluid (Hu et al., 2007) . In certain cell lines, ALA transport has been attributed to members of the SLC6 family of Na + -and Cl --coupled amino acid transporters, particularly the high-affinity GAT transporters (Rud et al., 2000; Bermúdez Moretti et al., 2002) . Therefore, ALA transport will vary depending upon the complement of amino acid and dipeptide transporters expressed in each cell type. The work presented here is the first study to demonstrate overlapping substrate specificity of distinct transporters for dipeptides and amino acids co-expressed in the same functional compartment of a cell.
Substantial transport of ALA into intestinal epithelial cells after oral ALA is evident by the accumulation of PpIX within normal intestinal mucosal tissue measured by fluorescent imaging (Loh et al., 1993; Regula et al., 1995) . However, the high background accumulation of PpIX in gastrointestinal epithelia is also a limiting factor in achieving sufficient PpIX This article has not been copyedited and formatted. The final version may differ from this version. tumor/normal mucosa ratios necessary for effective photodynamic therapy of gastrointestinal tumors. Thus, much higher doses of ALA are required (40-60mg/kg body weight) to achieve reasonable tumor selectivity in colon cancer compared to the oral doses used successfully in the detection of other tumors such as malignant glioma (10-20mg/kg body weight) (Loh et al., 1993; Regula et al., 1995 , Peng et al., 1997 Stummer et al., 2006) . The variation in accumulation of PpIX after ALA dosage, both between normal and tumor tissue and between different types of tumors, is still a matter of debate and is likely to be multi-factorial. Clearly, the first step required for in situ PpIX synthesis is the effective transport of ALA into the tumor cell. Therefore, increased ALA transport capacity may facilitate PpIX accumulation in combination with downstream effects such as the reduced ferrochelatase activity (which converts PpIX to heme) reported in some tumors (van Hillegersberg et al., 1992) . Figure 6 shows that both PepT1 and PAT1 are expressed in human colon cancer. The consistent increase in PepT1 expression in all tumor samples investigated is the first evidence that an ALA uptake mechanism may be altered in colon cancer. Upregulation of PepT1 in cancer may not be restricted to colonic tumors. [ 11 C]Gly-Sar has been found to accumulate in mouse tumor xenografts originating from human pancreatic, prostate and gastric cancer cells (Mitsuoka et al., 2008) . As well as influencing photodynamic therapy, increased PepT1 expression in cancer would be of potential therapeutic advantage in the delivery of the anticancer PepT1 substrate bestatin (Rubio-Aliaga and . It is tempting to speculate that the aberrant expression of H + -coupled transporters could provide a selective advantage for cancer cells by providing nutrient uptake pathways which can exploit the acid extracellular milieu associated with many solid tumors (Gerweck and Seetharaman, 1996) . Thus, selective inhibitors for such transporters could be a means to limit tumor nutritional supply. Further investigation is required to determine whether PepT1 functional capacity is increased in colon cancer.
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, this study shows that PAT1 is a novel transporter for ALA and that both PAT1 and PepT1 will contribute to the absorption of oral ALA across the brush-border 
